Literature DB >> 2222275

Echographic features of the Vogt-Koyanagi-Harada syndrome.

D J Forster1, M R Cano, R L Green, N A Rao.   

Abstract

Vogt-Koyanagi-Harada (VKH) syndrome represents a spectrum of bilateral panuveitis with associated central nervous system and dermatologic manifestations. The diagnosis is based on clinical and angiographic findings, but some of the characteristic features may be either absent or difficult to visualize in the presence of opaque media. With the use of standardized echography (standardized A-scan and contact B-scan echography), we examined nine patients with clear media and clinical evidence of VKH syndrome. Consistent echographic findings included (1) diffuse, low to medium reflective thickening of the choroid posteriorly; (2) serous retinal detachment, located inferiorly or in the posterior pole; (3) mild vitreous opacities with no posterior vitreous detachment; and (4) thickening of the sclera and/or episclera posteriorly. Resolution of these findings occurred with systemic corticosteroid therapy. Standardized echography should be considered an important diagnostic tool in VKH syndrome, especially when visualization of the fundus is poor or when clinical presentation is atypical.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2222275     DOI: 10.1001/archopht.1990.01070120069031

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  21 in total

1.  Ultrasound biomicroscopic study of ciliary body changes in the post-treatment phase of Vogt-Koyanagi-Harada disease.

Authors:  S Wada; T Kohno; N Yanagihara; M Hirabayashi; H Tabuchi; K Shiraki; T Miki
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 2.  Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Authors:  Steven Yeh; Lisa J Faia; Robert B Nussenblatt
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

3.  Comparison of the clinical features between posterior scleritis with exudative retinal detachment and Vogt-Koyanagi-Harada disease.

Authors:  Zheng Liu; Wei Zhao; Qingqin Tao; Song Lin; Xiaorong Li; Xiaomin Zhang
Journal:  Int Ophthalmol       Date:  2021-10-08       Impact factor: 2.031

4.  Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease.

Authors:  Tatsushi Kawaguchi; Shintaro Horie; Nadia Bouchenaki; Kyoko Ohno-Matsui; Manabu Mochizuki; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2009-01-17       Impact factor: 2.031

5.  Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease.

Authors:  Narsing A Rao; Amod Gupta; Laurie Dustin; Soon Phaik Chee; Annabelle A Okada; Moncef Khairallah; Bahram Bodaghi; Phuc Lehoang; Massimo Accorinti; Manabu Mochizuki; Tisha Prabriputaloong; Russell W Read
Journal:  Ophthalmology       Date:  2009-12-24       Impact factor: 12.079

6.  Vogt-Koyanagi-Harada disease presenting as optic neuritis.

Authors:  Ranjan Rajendram; Monica Evans; Rahul N Khurana; Julie H Tsai; Narsing A Rao
Journal:  Int Ophthalmol       Date:  2007-04-17       Impact factor: 2.029

7.  The spectrum of Vogt-Koyanagi-Harada disease in South India.

Authors:  Somasheila I Murthy; Mayur R Moreker; Virender S Sangwan; Rohit C Khanna; Sushma Tejwani
Journal:  Int Ophthalmol       Date:  2007-02-23       Impact factor: 2.029

8.  Alterations of color vision and central visual field in patients with Vogt-Koyanagi-Harada syndrome.

Authors:  Peizeng Yang; Min Sun; Xiaoli Liu; Hongyan Zhou; Wang Fang; Li Wang; Aize Kijlstra
Journal:  J Ophthalmic Inflamm Infect       Date:  2012-02-02

9.  TNFAIP3 gene polymorphisms in a Chinese Han population with Vogt-Koyanagi-Harada syndrome.

Authors:  Hong Li; Qing Liu; Shengping Hou; Liping Du; Qingyun Zhou; Yan Zhou; Aize Kijlstra; Peizeng Yang
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

10.  Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up.

Authors:  Carl P Herbort; Alessandro Mantovani; Nadia Bouchenaki
Journal:  Int Ophthalmol       Date:  2007-04-25       Impact factor: 2.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.